Publications

Export 11 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D [E] F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
E
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations–An Egyptian perspective", Journal of advanced research, vol. 7, issue 3: Elsevier, pp. 391-402, 2016. Abstract
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective", Journal of Advanced Research, vol. 7, issue 3: Elsevier, pp. 391 - 402, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.", Journal of advanced research, vol. 7, issue 3, pp. 391-402, 2016 May. Abstract

Egypt, the single country with highest incidence of HCV infection in the world, has embarked on a government-sponsored mass treatment program using several combinations of DAAs. Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a subcommittee was assigned to develop national guidelines for respective prioritizing indications and protocols. It evaluated the benefit of treating patients with different extrahepatic manifestations, and reviewed relevant clinical trials and guidelines concerning DAA combinations available in Egypt. The latter included Sofosbuvir plus either peg-interferon, Simeprevir, Ledipasvir or daclatasvir, and the Viekera family comprising paritaprevir/ritonavir + ombitasvir with (GT-1) or without (GT-4) Dasabuvir. Any of these protocols may be used with or without Ribavirin according to indication. A blueprint was subjected to peer debate in dedicated workshops in two national meetings and subsequently to an online professional review, eventually leading to a final report that was adopted by the health authorities. Seven compelling and 10 optional indications were identified for treating patients with predominantly extrahepatic manifestations. The former include kidney disease at different stages, cryoglobulinemic vasculitis and non-Hodgkin lymphoma. Selected treatment protocols, were encoded and their use was prioritized on the basis of evidence of efficacy and safety. We concluded that any of the studied protocols may be used, preferably with ribavirin, for 12-week treatment in all patients with extrahepatic manifestations without cirrhosis and with eGFR above 30 ml/min/1.73 sqm. Ribavirin should be included in protocols for treating patients with compensated cirrhosis. Daclatasvir-based protocols are recommended for decompensated cirrhosis, while the Viekera family is recommended in patients with eGFR < 30 ml/min/1.73 sqm, including those on dialysis. In kidney-transplanted patents, caution is due to avoidance of the pharmacokinetic interaction with the Cytochrome-P450 enzyme system, in-between immunosuppressive agents and most DAAs, particularly the Viekera family.

El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases", Journal of Clinical Rheumatology, vol. 22, issue 5: Lippincott Williams and Wilkins, pp. 264 - 271, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy Masquerading as Systemic Rheumatic Diseases.", Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, vol. 22, issue 5, pp. 264-71, 2016 Aug. Abstract

Rheumatologic manifestations not only are encountered in leprosy but also can be the first and even the sole presenting manifestation. The hallmark of leprosy is skin and peripheral nerve affection; however, it can affect a wide range of other organs, with the joints being the commonest. We have searched PubMed with the key words leprosy, arthritis, vasculitis, rheumatic diseases, and autoantibodies in a proper combination. Relevant studies were retrieved from scanning of their abstracts. The relevant references provided in these articles were also selected and reviewed. We summarize the clinical and laboratory manifestations that make leprosy masquerade as a systemic rheumatic disease. Moreover, we report 4 Egyptian patients who presented with rheumatologic manifestations, namely, arthritis and vasculitis that turned out to be leprosy related.

El-Gendy, H., R. M. El-Gohary, K. S. Shohdy, and G. Ragab, "Leprosy masquerading as systemic rheumatic diseases", JCR: Journal of Clinical Rheumatology, vol. 22, issue 5: LWW, pp. 264-271, 2016. Abstract
n/a
El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature", Platelets, vol. 30, issue 5: Taylor and Francis Ltd, pp. 664 - 671, 2019. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature", Platelets, vol. 30, issue 5: Taylor & Francis, pp. 664-671, 2019. Abstract
n/a
El-Gendy, H., R. M. El-Gohary, S. Mahfouz, H. M. A. Ahmed, D. M. El Demerdash, and G. Ragab, "Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature.", Platelets, pp. 1-8, 2018 Oct 29. Abstract

Avascular necrosis (AVN) is a devastating condition that is rarely reported in patients with immune thrombocytopenia (ITP). Treatment with steroids remains a major risk factor for developing AVN. However, the incidence of AVN in patients with ITP requiring corticosteroid therapy is much less than that observed with other clinical conditions requiring corticosteroids. ITP is a bleeding disorder but can be also be a pro-thrombotic state via different mechanisms and thus could result in AVN. Among the possible causes of this pro-thrombotic state is the presence of antiphospholipid antibodies (aPLs). In this case, we report a patient with refractory ITP who developed multifocal AVN around the time she acquired new aPLs. We also discuss different mechanisms by which risk of thrombosis is increased in ITP and the relationship between ITP, aPLs and antiphospholipid syndrome.

Elbendary, A., M. R. E. Abdel-Halim, and G. Ragab, "Updates in cutaneous manifestations of systemic vasculitis", Current opinion in rheumatology, vol. 34, issue 1: NLM (Medline), pp. 25 - 32, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a